Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Unknown

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of VG161 in Combination With Nivolumab in Patients With Advanced Pancreatic Cancer

Outcome
Outcome unknown
Phase
Phase 1 / Phase 2
Status
Unknown
Study type
Interventional
Start
8 March 2022
Listed end
22 December 2025
Enrollment
51 participants
Sites
1
Primary outcomes
MTD; Occurrence and numbers of DLT (phase 1); Occurence and frequence of AE and SAE (phase 1); DCR (phase 2); RP2D (phase 1)
Sponsor type
Academic / other
Results posted
No
Last update
9 March 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).

Detailed description public domain (ClinicalTrials.gov)

A multicenter, open, single-arm design of clinical trial of VG161 in combined with PD-1 inhibitor (Nivolumab) in the treatment of patients with advanced pancreatic cancer with metastasis. The standard 3 + 3 design was used in the dose-finding study to explore the safety of the combination treatment, determine the recommended safe dose (RP2D) of the combination treatment in the second phase of efficacy study. The first cycle was observed until Day 28, i.e., DLT observation period. In the efficacy investigation trial, Simon two-segment design was used to continue to investigate the preliminary efficacy of the combination at a safe dose.